An interventional study of PEI+GT and PEI+MED in Glaucoma, Open-Angle, Cataract Complicated and Goniotomy, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-12-11.
Sponsored by Sun Yat-sen University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Glaucoma, Open-Angle with a site in China — 7 open to participants now, 11 under way, 1 of them phase 3. Glaucoma, Open-Angle · China.
Among the 38 studies in Glaucoma, Open-Angle with a site in China, this one is the 18th largest by planned enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2023, is one of 14 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 30th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →7 of the 38 studies in Glaucoma, Open-Angle with a site in China are open now. Recruiting first, the newest first:
Nanfang Hospital, Southern Medical University · Sites in China
Ages 40–85
Zhongnan Hospital · Sites in China
Ages 16–80
Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. · Sites in China
Ages 18–80
IVIEW Therapeutics Inc. · Sites in China
Ages 18–75
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 18–75 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 7 · Phase 4 6
First in 2005; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 120 across the 30 interventional studies, 200 across the 8 observational. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 38 have an industry lead sponsor. The 10 most frequent:
Sun Yat-sen University is the lead sponsor of 1,695 studies on the registry; 622 are open to participants now.
Sun Yat-sen University has 1 study filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
1 of the studies in Glaucoma, Open-Angle with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07777861Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies in Glaucoma, Open-Angle with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this multicenter non-inferiority randomized controlled trial is to compare the efficacy of phacoemulsification with intraocular lens implantation (PEI) combined with goniotomy (GT) and PEI combined with medical therapy (MED) in the treatment of medically-controlled primary open-angle glaucoma (POAG) with cataract. The main questions it aims to answer are:
Glaucoma is the leading cause of irreversible blindness worldwide, with primary open-angle glaucoma (POAG) remaining the most common subtype.
Although there are various methods to treat POAG, medication remains the first choice. However, medication therapy has several limitations, such as multiple adverse effects, poor compliance, and high costs. Therefore, it is imperative to explore treatment modalities that reduce medication burden and improve patients' quality of life.
Minimally invasive glaucoma surgery (MIGS) has been widely employed in clinical practice in recent years and become the mainstream surgical approach for POAG treatment. Among them, various forms of Schlemm's canal-based procedures, which were commonly known as ab interno trabeculotomy or goniotomy (GT) have garnered clinical significance due to their advantages of simplicity, minimal invasiveness, low complication rates, and rapid recovery. These procedures can also be combined with phacoemulsification with intraocular lens implantation (PEI). Currently, several GT techniques have been reported using different devices with different ranges of incision. The investigators have proved that a 120-degree GT with or with PEI were effective enough to treat patients with POAG with or without cataract, providing a comparable efficacy with 240 or 360 degree GT. The 120-degree is characterized by not only its efficacy, but also its fewer complications, faster procedure and quicker recovery. Although the techniques have been implemented clinically, further research is needed to evaluate their economics value in terms of reducing patient dependence on medication, relieving the economic burden of glaucoma medications, and improving the quality of life.
Therefore, a non-inferiority randomized controlled trial (RCT) will be conducted in medically controlled POAG patients with cataract, comparing PEI+GT to PEI combined with medication therapy (PEI+MED). The trial aims to validate the effectiveness of GT in reducing medication use, lightening the burden on patients, and providing a novel treatment approach.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pregnant or lactating women.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental group: Phacoemulsification with intraocular lens implantation (PEI) and goniotomy (GT).
Procedure: PEI+GT
Controll group: Phacoemulsification with intraocular lens implantation (PEI) and medication therapy (MED).
Procedure: PEI+MED
After a standard phacoemulsification with intraocular lens implantation (PEI) is performed. The viscoelastic substance will be injected into the anterior chamber again to maintain corneal rigidity. The surgical microscope will be adjusted to tilt 35-40° towards the patient's nasal side, and the patient's head position will be adjusted to tilt 35-40° accordingly. A viscoelastic substance will be applied to the corneal surface to facilitate direct visualization of the angle structures under a gonioscope. The Tanito Microhook will be inserted through the main incision into the anterior chamber, and under gonioscopic guidance, the nasal (or inferonasal) trabecular meshwork and the inner wall of Schlemm's canal will be incised, approximately 120° in extent (60° in each direction).
Participants assigned to control group will undergo routine PEI surgery. Postoperatively, the decision to administer anti-glaucoma medication is based on intraocular pressure (IOP) measurements, and the target IOP is set at 16 mmHg. The selection of medications is informed by the Asia Pacific Glaucoma Guidelines (Kugler Publications, 2016), while the target IOP reference is the European Glaucoma Guidelines.
IOP at 12 months after surgery.
The intraocular pressure (mmHg) at 12 months after surgery.
Time frame: Postopertive 12 months.
Surgery success of surgery
(i) Complete success (%) is defined as the postoperative 5 \< IOP ≤ 16 mmHg with no need for IOP-lowering medication, without any vision-threatening complication or need for re-operation. (ii) Qualified success (%) is defined as the postoperative 5 \< IOP ≤ 16 mmHg regardless of IOP-lowering medication, without any vision-threatening complication or need for re-operation.
Time frame: Postoperative 3, 6, 12 months.
Amount of postoperative anti-glaucomatous medications
The amount of postoperative anti-glaucomatous medications will be measured as: types of medication (No.) × time (No.).
Time frame: Postoperative 1, 3, 6, 12 months.
Cost-effectiveness associated parameters
Cost-effectiveness associated parameters: cost of surgery and medications; quality-adjusted life year, etc.
Time frame: Postoperative 12 months.
Surgery complications
Incidence of surgery complications.
Time frame: Postoperative 1, 3, 6, 12 months.
Visual acuity
Unit: logMAR
Time frame: Postoperative 1, 3, 6, 12 months.
Corneal endothelial cell counting
Unit: cells/mm\^2
Time frame: Postoperative 12 months.
Visual field
Mean deviation (MD) and pattern standard deviation (PSD) using Humphrey perimetery
Time frame: Postoperative 12 months.
Optic nerve head morphology and retinal parameters based on optical coherence tomography
Thickness (μm) of peripapillary retinal nerve fiber layer and macular GC-IPL are collected from optical coherence tomography device.
Time frame: Postoperative 12 months.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Sep 2026, 36 months after the start.
Of 101 non-industry interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 36 months is close to that.
Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.